Publications by authors named "R Lauria"
Article Synopsis
- PARP inhibitors, specifically niraparib, are used in maintenance therapy for platinum-sensitive ovarian cancer, regardless of BRCA mutation status.
- A study evaluated the real-world efficacy and safety of niraparib in patients with relapsed ovarian cancer, collecting clinical data from those who received the treatment.
- Results showed a median progression-free survival of 9.1 months for BRCA wild-type patients and 10.3 months for BRCA mutated patients, indicating that niraparib is effective and well tolerated in clinical practice.
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Int J Gynecol Cancer
October 2021
Article Synopsis
- Routine antithrombotic prophylaxis is not advised for advanced cancer patients undergoing chemotherapy, and the impact of bevacizumab on thromboembolic risks in ovarian cancer is unclear.
- A secondary analysis of the MITO-16A/MaNGO-OV2A trial assessed thromboembolic events and antithrombotic therapy among patients receiving platinum-based chemotherapy with bevacizumab.
- The study found a 6.0% incidence of thromboembolic events which were not linked to patient characteristics, antithrombotic use, or overall survival outcomes.
The gastrointestinal tract may be a site of origin for α-synuclein pathology in idiopathic Parkinson's disease (PD). Disruption of the autophagy-lysosome pathway (ALP) may contribute to α-synuclein aggregation. Here we examined epigenetic alterations in the ALP in the appendix by deep sequencing DNA methylation at 521 ALP genes.
View Article and Find Full Text PDFIntroduction: The role of cytoreductive surgery in the poly-ADP ribose polymerase inhibitors era is not fully investigated. We evaluated the impact of surgery performed prior to platinum-based chemotherapy followed by olaparib maintenance in platinum-sensitive BRCA-mutated recurrent ovarian cancer.
Methods: This retrospective study included platinum-sensitive recurrent ovarian cancer BRCA-mutated patients from 13 Multicenter Italian Trials in Ovarian cancer and gynecological malignancies centers treated between September 2015 and May 2019.
Objective: To explore the clinical and biological prognostic factors for advanced ovarian cancer patients receiving first-line treatment with carboplatin, paclitaxel, and bevacizumab.
Methods: A multicenter, phase IV, single arm trial was performed. Patients with advanced (FIGO (International Federation of Gynecology and Obstetrics) stage IIIB-IV) or recurrent, previously untreated, ovarian cancer received carboplatin (AUC (area under the curve) 5), paclitaxel (175 mg/m) plus bevacizumab (15 mg/kg) on day 1 for six 3-weekly cycles followed by bevacizumab single agent (15 mg/kg) until progression or unacceptable toxicity up to a maximum of 22 total cycles.